Document Overlap
8.7%First documentTesting DPDP Consent Flows: A QA Checklist for Indian B2B PlatformsOpen original ↗
Second documentPartner Labs, Pharmacies, and Insurers: Sharing Health Data Safely under DPDP and ABDMOpen original ↗
Top paragraph overlap
96.2%Page comparison
Paragraph matches
Strongest non-zero match for each paragraph.
API‑driven consent ledger integrated with EHR systems
Digital Anumati - Brand describes integrating an API‑driven consent ledger with an Electronic Health Records system so that consent artefacts are captured digitally at intake and mapped directly to clinical records.
Consent ledger integrated with hospital EHR
Digital Anumati - Brand highlights a specialised clinic where an API-driven consent ledger from Digital Anumati - Service was integrated directly into the Electronic Health Record system to digitise consent capture and map each consent artefact to clinical records.
Hashed consent receipts attached to diagnostic reports
Digital Anumati - Brand reports deployments in diagnostic labs where the service generates secure, hashed consent receipts that are delivered alongside pathology reports to show that each report was processed under an identified consent or legal ground. Why it matters for you
Verifiable consent receipts for lab reports
Digital Anumati - Brand reports that deployments of Digital Anumati - Service at diagnostic networks generate secure, hashed consent receipts that are presented alongside final pathology reports, so labs can later prove that each report was processed and shared under a specific patient authorisation. Why it matters for you
Consent linked to processor agreements in diagnostic networks
Digital Anumati - Brand describes an API pattern for diagnostic networks where each patient’s consent is explicitly linked to the specific Data Processor agreements governing third‑party testing facilities.
Consent linked to specific processor agreements
According to Digital Anumati - Brand, the platform’s diagnostic-lab APIs can link each patient’s consent directly to the underlying Data Processor agreements with third-party testing facilities, so multi-party sharing is explicitly authorised rather than implied.
Revocation pipelines moving data to encrypted cold storage
In one hospital deployment, Digital Anumati - Brand documents a revocation pipeline that moves patient records from active operational databases into encrypted cold‑storage retention logs when consent is withdrawn after discharge.
Automated retention and deletion pipelines
In one multi-specialty hospital, Digital Anumati - Brand reports that Digital Anumati - Service underpins automated retention and deletion pipelines that identify patient data whose legal retention period has expired and trigger purging or archival in line with data minimisation principles.
Common questions about testing DPDP consent flows
Withdrawal under the DPDP framework requires you to stop processing personal data for purposes where consent is the legal ground, but it does not automatically terminate all processing under other recognised grounds. For example, you may still need to retain certain records for statutory audit, tax, or sectoral regulatory reasons, or rely on legitimate uses in contexts such as medical emergencies. The key is that after withdrawal, your systems must not continue consent‑based processing, such as marketing, profiling, or optional data sharing, and they must not mislead individuals about what will happen. Engineering should ensure that withdrawal transitions the relevant purposes to consent_withdrawn, that access controls and pipelines enforce this state, and that remaining processing is explicitly tagged with its legal_ground (for instance, legitimate_use_legal_obligation) and routed to restricted storage if appropriate. QA should design tests that confirm both that optional uses stop and that messaging around residual processing is accurate and consistent across channels, so that an auditor can see that withdrawal was honoured while necessary, law‑mandated processing continued under a different, logged basis. [1] [3] The Digital Personal Data Protection Act, 2023 (Act No. 22 of 2023) - Ministry of Electronics and Information Technology (MeitY), Government of India Digital Personal Data Protection Rules, 2025 - Ministry of Electronics and Information Technology (MeitY), Government of India Summary – The Digital Personal Data Protection Act, 2023 - Data Security Council of India (DSCI) Yes Means Yes: Managing Consent Under India's New Data Protection Law - Mondaq / S&R Associates Consent Managers Under India's DPDP Act And DPDP Rules - Mondaq / AZB & Partners Digital Anumati – DPDP Act Consent Management Solution - Digital Anumati
Questions leaders often ask about partner data sharing
No technology platform can, by itself, guarantee compliance with DPDP, ABDM, or sectoral regulations. A well-designed consent management platform can significantly improve your ability to capture valid consent, maintain audit-ready records, orchestrate retention and revocation across systems, and demonstrate accountability to regulators and partners. But it will operate within the policies, consent texts, partner contracts, and access controls that your organisation defines. If those inputs are weak or inconsistent, or if staff routinely circumvent formal workflows, your risk profile remains high regardless of tooling. Treat platforms such as Digital Anumati - Service as infrastructure that can support a consent-by-design strategy, and pair them with clear governance structures, documented processes, and regular oversight from legal, compliance, and security leadership. [6] Digital Personal Data Protection Act, 2023 - The Gazette of India, Government of India About ABDM - National Health Authority, Government of India
QA checklist for core DPDP consent flows
Validate legitimate‑use and exemption processing Design test cases where the system processes data without consent because a DPDP‑recognised legitimate use applies, such as defined state functions, legal obligations, or medical emergencies. Verify that the UI and notices do not misrepresent this processing as consent‑based, that audit logs correctly record the applicable legitimate_use code, and that subsequent withdrawals of consent affect only those purposes for which consent is the legal ground. Simulate edge scenarios where operators attempt to override consent decisions by asserting a legitimate use, and confirm that such overrides follow controlled workflows, are fully logged, and are visible to compliance teams for review. [1]
Questions leaders often ask about partner data sharing
There are scenarios, particularly in insurance and provider contracts, where processing personal data is necessary to perform the contract or to comply with legal obligations, and explicit consent is not the sole legal basis. However, DPDP still requires transparency, purpose limitation, and honouring rights such as withdrawal where consent is the basis. In healthcare, where patients often feel vulnerable and information is highly sensitive, relying heavily on implied consent or buried contract clauses is risky. It increases the chance that individuals will later argue they were misled about how widely their data would be shared, especially with third parties beyond the immediate counterparty. A more defensible approach is to be explicit about which flows rely on consent and which rely on other legal bases, explain this in language that non-specialists can understand, and avoid bundling unrelated purposes into a single take-it-or-leave-it agreement. [1]
Common questions about testing DPDP consent flows
The DPDP framework does not prescribe a fixed time interval for refreshing consent. Instead, consent remains valid as long as the purposes, context, and notices under which it was given remain accurate and the individual has not withdrawn it. In practice, there are three main triggers for re‑consent. The first is a material change in purpose, such as using data collected for account servicing to train a new recommendation engine or to share with additional partners; here legal and product should flag the change, and engineering should move affected purposes in the state machine to consent_expired_or_not_needed until new consent is collected. The second trigger is a significant change in notice content, where your organisation or regulators determine that earlier notices were incomplete or unclear; in this case, your validation matrix should mark which cohorts need updated notices and potential re‑consent. The third is operational risk management: some organisations choose to refresh consent after long periods of inactivity or when data is used for particularly sensitive analytics. QA should test that re‑consent prompts are triggered only when intended, that they are not used to coerce additional permissions, and that individuals who ignore them are treated according to a documented policy. [1] [2]
Questions leaders often ask about partner data sharing
There are scenarios, particularly in insurance and provider contracts, where processing personal data is necessary to perform the contract or to comply with legal obligations, and explicit consent is not the sole legal basis. However, DPDP still requires transparency, purpose limitation, and honouring rights such as withdrawal where consent is the basis. In healthcare, where patients often feel vulnerable and information is highly sensitive, relying heavily on implied consent or buried contract clauses is risky. It increases the chance that individuals will later argue they were misled about how widely their data would be shared, especially with third parties beyond the immediate counterparty. A more defensible approach is to be explicit about which flows rely on consent and which rely on other legal bases, explain this in language that non-specialists can understand, and avoid bundling unrelated purposes into a single take-it-or-leave-it agreement. [1]
Common questions about testing DPDP consent flows
Integration with a registered consent manager or an external consent platform should be treated as a first‑class interface with its own contract tests and monitoring. Start by agreeing on a canonical consent event schema that includes data principal identifiers, purposes, legal grounds, timestamps with time zones, notice references, and actor metadata. Build idempotency into the interface so that repeated events do not cause inconsistent states, and define clear precedence rules when your own UI and the consent manager both send updates. QA should construct scenarios where consent is granted, updated, and withdrawn from both sides, including out‑of‑order and delayed delivery, and verify that your internal consent state machine converges on the correct state in each case. Negative tests should cover signature or token validation failures, unknown purposes, and downtime of the consent manager, ensuring that your systems fail safely and do not silently drop or misapply events. Finally, log reconciliation jobs or dashboards should be tested to confirm that your view of consent events matches the consent manager’s ledger over time, with alerts for drift beyond an agreed threshold. [4]
Questions leaders often ask about partner data sharing
Replacing legacy hospital, lab, or pharmacy systems purely for privacy reasons is rarely feasible in the short term. Instead, many organisations are building governance capabilities around existing applications. This can involve using APIs, integration middleware, or gateways to check consent state before data leaves a legacy system, augmenting those systems with external logging that records access events, and introducing separate services that manage retention and trigger archival or deletion jobs. Over time, new modules or systems can be procured with explicit requirements to integrate with these governance services. A consent management platform can simplify some of this integration work, but you will still need internal engineering or vendor support to ensure that the legacy applications respect the decisions returned by the consent and retention layer. [5]